---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-414364"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2026-10-05T21:06:37+00:00"
generated_at: "2026-10-12T16:41:15.836446+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Equillium wins Australian HREC and TGA clearance for Phase 1 EQ504 trial; dosing to start early November 2026

## Summary
- Equillium received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia under the Clinical Trial Notification scheme for a Phase 1 trial of EQ504.
- Company expects to begin dosing healthy participants by early November 2026.
- Phase 1 is a randomized, double-blinded, placebo-controlled, single-center study of once-daily oral EQ504 at doses from 0.1 mg to 3.0 mg.
- Part A: single ascending dose across 5 cohorts; Part B: multiple ascending dose across 3 cohorts with 10 days of once-daily dosing to assess steady-state PK, safety and tolerability.
- Part C: food-effect crossover cohort testing a high-fat meal's impact on bioavailability; longitudinal GI mucosal biopsies will assess CYP1A1 expression for target validation ahead of Phase 2.

## SEC filing metadata
- accession: 0001193125-26-414364
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2026-10-05T21:06:37+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312526414364/0001193125-26-414364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312526414364/d174431d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-414364
- JSON: https://secwatch.observer/filing/0001193125-26-414364.json
- Plain text: https://secwatch.observer/filing/0001193125-26-414364.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.